Yunkang Group (HKG:2325) expects a net loss between 663 million yuan and 856 million yuan in 2024, wider than 101.9 million yuan in 2023, a Tuesday Hong Kong bourse filing said.
The medical operation service provider attributed the expected wider loss to lower revenue from diagnostic testing services due to market conditions and higher provision for credit impairment losses, optimization expenses, and research and development expenses.
Price (HKD): $4.87, Change: $-0.0100, Percent Change: -0.20%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.